Roche Holding, CH1499059983

Roche Holding stock gains FDA approval for kidney disease drug

Published on 11/18/2026 at 11:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding stock gains a new regulatory foothold in kidney disease. The FDA cleared Gazyva/Gazyvaro as the first approved treatment for primary membranous nephropathy.

Roche expands immune-disease reach

  • Gazyva/Gazyvaro became the first FDA-approved treatment for primary membranous nephropathy.
  • The phase III MAJESTY study showed complete proteinuria remission in 36.1% of patients after two years, versus 5.7% with tacrolimus.
  • The FDA is expected to decide on Roche's systemic lupus erythematosus application by December 2026.
Roche Holding, CH1499059983, Illustration mit AI erstellt.

On Monday, November 16, 2026, Roche said in a Roche release that the U.S. Food and Drug Administration had approved Gazyva/Gazyvaro, also known as obinutuzumab, for adults with primary membranous nephropathy at risk of disease progression. The treatment is intended to induce remission of proteinuria, a key indicator of kidney damage.

The decision gives Roche the first FDA-approved therapy specifically for primary membranous nephropathy, a chronic autoimmune condition that can cause progressive kidney damage and kidney failure. Roche said the approval expands the use of Gazyva/Gazyvaro across immune-mediated kidney diseases and marks its third FDA approval in that area, following approvals for idiopathic nephrotic syndrome and lupus nephritis.

MAJESTY results support approval

The approval was based on the phase III MAJESTY study, which enrolled 142 adults and compared Gazyva/Gazyvaro with tacrolimus. At 104 weeks, complete remission of proteinuria was achieved by 36.1% of adults receiving Gazyva/Gazyvaro, compared with 5.7% in the tacrolimus group. Roche reported an adjusted difference of 31.1 percentage points and a p-value below 0.001.

Overall remission, including complete or partial remission, reached 50% at week 104 with Gazyva/Gazyvaro, versus 12.9% with tacrolimus. Complete remission at week 76 was 36.1% and 8.6%, respectively. Roche said safety was consistent with the established profile of the medicine and that the study revealed no new safety signals.

Further kidney and lupus opportunities

Roche Chief Medical Officer Levi Garraway said the approval supports a treatment approach focused on B cells, which are a key driver of the disease. The company said the MAJESTY findings were presented at the European Renal Association Congress in June 2026 and published in the New England Journal of Medicine.

The regulatory decision adds a new commercial opportunity to Roche's immunology portfolio while broadening the potential reach of an existing medicine. The company said submissions are also being prepared for other health authorities, including the European Medicines Agency. The FDA is reviewing Gazyva/Gazyvaro for systemic lupus erythematosus, with a decision expected by December 2026. The European Medicines Agency's medicines committee has already issued a positive opinion recommending approval for that indication.

Roche Holding stock traded at 438.98 euros on Lang & Schwarz at 11:30 CET on Wednesday, November 18, 2026.

Roche Holding at a glance

  • Company: Roche Holding AG
  • ISIN: CH1499059983
  • Exchange: SIX Swiss Exchange
  • Ticker: RO and ROP
  • Price: 438.98 euros on Lang & Schwarz, Wednesday, November 18, 2026, at 11:30 CET

Broader market coverage is available in Current market reports.

The Swiss equity market context is covered by the SMI.

More news and analyses on Roche Holding stock.

Disclaimer...
en | CH1499059983 | ROCHE HOLDING | boerse | 70530494 | bgmi